?A comprehensive review of the recent developments in DNA repair research that have potential for translational applications. The book explains in detail the various biological mechanisms by which cancer cells can circumvent anticancer therapy and limits its usefulness in patients. They also review the impact of such novel inhibitors of DNA repair mechanisms as methylguanine-DNA-methyltransferase. Also examined are inhibitors of other DNA repair enzymes such as PARP and DNA-PK. The book captures-for both cancer researchers and oncologists dealing with hallmark "relapse" or "drug resistance" phenomena on a daily basis-the many exciting new uses of DNA repair inhibitors, either alone or in combination with anticancer therapies.?

This book deals with the emerging role of various DNA repair proteins and the regulatory elements which are implicated in cancer therapy such as DNA cross-linking agents, radiotherapy and bleomycin.  The DNA repair genes discussed include those involved in BRCA/Rad51-related homologous recombinational repair, DNA-PK related nonhomologous endjoining and the nucleotide excision repair gene, ERCC1.  Moreover, the role of regulatory genes such as PARP, ATR, telomerase, growth factor receptors and downstream kinase signalling  is examined.